Caldera Therapeutics
PrivateLast Round
Series A
Extension
Jan 14, 2026
Total Funding Raised
$112.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Caldera Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A Extension round in January 2026.
Caldera Therapeutics is a clinical stage biotechnology company developing CLD-423, a first-in-class bispecific antibody for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Caldera Therapeutics Comparables
Compare Caldera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bionyra Pharma | 94% | |
| TrueLab Biopharmaceutical | 88% | |
| Spyre Therapeutics Inc. | 84% |
For institutional investors. Book with your work email.
Caldera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 14, 2026 | ||||
| Series A | Apr 23, 2025 |
For institutional investors. Book with your work email.
Caldera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A Extension |
| Omega Funds | Series A Extension |
| Accomplice | Series A Extension, Series A |
| venBio | Series A Extension, Series A |
| Wellington Management | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
Grew 42% QoQ, from 12 to 17 employees.
- Aug 21, 2026
Monthly visitors grew 108% MoM, reaching 4.2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresNov 10, 2026
Caldera Therapeutics, Inc. names Lee Giguere, JD, as chief legal officer on Nov 10th '26; he brings more than 20 years of experience as the company prepares to become publicly traded and advances its IBD program into Phase II.
For institutional investors. Book with your work email.
Caldera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Caldera Therapeutics's valuation, stock price, and market status.
Is Caldera Therapeutics a public or private company?
Caldera Therapeutics is a private company.
What is the current stock price of Caldera Therapeutics?
Caldera Therapeutics is a private company, so its shares have no public market price. Caplight tracks Caldera Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Caldera Therapeutics worth (valuation)?
Valuation information for Caldera Therapeutics is not publicly available.
Can I buy Caldera Therapeutics stock?
Caldera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Caldera Therapeutics's last funding round?
Caldera Therapeutics's most recent funding round was Series A Extension on January 14, 2026.
Who are the main investors in Caldera Therapeutics?
Key investors in Caldera Therapeutics include Omega Funds.
Will Caldera Therapeutics IPO soon?
No public IPO plans have been announced for Caldera Therapeutics.
How can I track Caldera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Caldera Therapeutics's shares on secondary markets.